Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AB-16B5 Combined With Docetaxel in Previously Treated Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

NCT04364620 is registered in ClinicalTrials.gov with Alethia Biotherapeutics as lead sponsor.

NCT NCT04364620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AB-16B5 Combined With Docetaxel in Previously Treated Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
Lead sponsor
Alethia Biotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 23, 2021
Completion date
December 31, 2023
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv